Uniqure NV (QURE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Uniqure NV (QURE) has a cash flow conversion efficiency ratio of -0.072x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.40 Million) by net assets ($228.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Uniqure NV's balance sheet to measure how much of total assets are equity-financed.
Uniqure NV - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Uniqure NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check QURE cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Uniqure NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Uniqure NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningbo Yongxin Optics Co Ltd
SHG:603297
|
0.024x |
|
Jiangsu Huahong Technology Co Ltd
SHE:002645
|
-0.010x |
|
Tennant Company
NYSE:TNC
|
-0.059x |
|
uniQure N.V
F:UQ1
|
-0.256x |
|
IRSA Inversiones y Representaciones SA
BA:IRSA
|
0.017x |
|
Leggett & Platt Incorporated
NYSE:LEG
|
-0.054x |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
0.002x |
|
Elan Microelectronics Corp
TW:2458
|
0.095x |
Annual Cash Flow Conversion Efficiency for Uniqure NV (2011–2024)
The table below shows the annual cash flow conversion efficiency of Uniqure NV from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see QURE market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-6.75 Million | $-182.73 Million | 27.063x | +3951.28% |
| 2023-12-31 | $207.67 Million | $-145.93 Million | -0.703x | -130.59% |
| 2022-12-31 | $476.01 Million | $-145.06 Million | -0.305x | -163.05% |
| 2021-12-31 | $595.78 Million | $287.96 Million | 0.483x | +187.44% |
| 2020-12-31 | $243.91 Million | $-134.83 Million | -0.553x | -80.96% |
| 2019-12-31 | $323.06 Million | $-98.68 Million | -0.305x | +27.85% |
| 2018-12-31 | $179.61 Million | $-76.04 Million | -0.423x | +40.75% |
| 2017-12-31 | $89.94 Million | $-64.27 Million | -0.715x | +37.02% |
| 2016-12-31 | $63.63 Million | $-72.19 Million | -1.134x | -889.30% |
| 2015-12-31 | $130.63 Million | $18.78 Million | 0.144x | +124.36% |
| 2014-12-31 | $52.39 Million | $-30.92 Million | -0.590x | +20.61% |
| 2013-12-31 | $7.68 Million | $-5.71 Million | -0.743x | -102.95% |
| 2012-12-31 | $-592.48K | $-14.91 Million | 25.172x | +290.73% |
| 2011-12-31 | $-3.36 Million | $-21.65 Million | 6.442x | -- |
About Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more